Comparative Study of Low-dose Pioglitazone or Metformin Treatment in Ia pa nese Diabetic Patients with Metabolic Syndrome

T. Kato, Y. Sawai, H. Kanayama, H. Taguchi, T. Terabavashi, F. Taki, K. Yamada, Y. Yamazaki, N. Hayakawa, Atsushi Suzuki, N. Oda, N. Katada, M. Itoh

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The aim of this study was to determine whether a relatively low dose of pioglitazone or metformin was effective in diabetic patients with metabolic syndrome. Fifty diabetic patients with metabolic syndrome were randomly assigned to a low-dose pioglitazone (15mg/day) treatment group or a low-dose metformin (500mg/day) treatment group. Drugs were administered for 12 weeks. Systolic and diastolic blood pressure, heart rate, body mass index, triglyceride (TC), HDL and LDLcholesterol, fasting plasma glucose (FPG), fasting plasma insulin (IRI), postprandial glucose, and HOMA-IR in the 75gOGTT, HbA1c, high-sensitivity CRP (hs-CRP) determined by cervical artery echography, and pulse wave velocity (PWV) were measured before/after 12-week drug administra-tion. Significant decreases in HbA1c and HOMAIR were noted in the pioglitazone group, along with significant decreases in TG, AST, ALT, blood pressure, hs-CRP and PWV. Significant decreases in HbAIc, HOMA-IR, BMI and waist circumference were noted in the metformin group. The pioglitazone group significantly improved the values for ALT, systolic blood pressure, hs-CRP and PWV compared to the metformin group. However, the metformin group demonstrated significant improvement in BMI compared with the pioglitazone group. Using a low dose regimen, pioglitazone significantly improved blood pressure and hepatic function and may be more effective than metformin to reduce risk factors in Japanese diabetic patients with metabolic syndrome at preventing atherosclerosis.

Original languageEnglish
Pages (from-to)593-599
Number of pages7
JournalExperimental and Clinical Endocrinology and Diabetes
Volume117
Issue number10
DOIs
Publication statusPublished - 01-11-2009

Fingerprint

pioglitazone
Metformin
Pulse Wave Analysis
Blood Pressure
Fasting
Therapeutics
Glucose
Waist Circumference
Pharmaceutical Preparations
Ultrasonography
Atherosclerosis
Triglycerides
Body Mass Index
Arteries
Heart Rate
Insulin

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Kato, T. ; Sawai, Y. ; Kanayama, H. ; Taguchi, H. ; Terabavashi, T. ; Taki, F. ; Yamada, K. ; Yamazaki, Y. ; Hayakawa, N. ; Suzuki, Atsushi ; Oda, N. ; Katada, N. ; Itoh, M. / Comparative Study of Low-dose Pioglitazone or Metformin Treatment in Ia pa nese Diabetic Patients with Metabolic Syndrome. In: Experimental and Clinical Endocrinology and Diabetes. 2009 ; Vol. 117, No. 10. pp. 593-599.
@article{0e32de2050814912873e72c6537b3a02,
title = "Comparative Study of Low-dose Pioglitazone or Metformin Treatment in Ia pa nese Diabetic Patients with Metabolic Syndrome",
abstract = "The aim of this study was to determine whether a relatively low dose of pioglitazone or metformin was effective in diabetic patients with metabolic syndrome. Fifty diabetic patients with metabolic syndrome were randomly assigned to a low-dose pioglitazone (15mg/day) treatment group or a low-dose metformin (500mg/day) treatment group. Drugs were administered for 12 weeks. Systolic and diastolic blood pressure, heart rate, body mass index, triglyceride (TC), HDL and LDLcholesterol, fasting plasma glucose (FPG), fasting plasma insulin (IRI), postprandial glucose, and HOMA-IR in the 75gOGTT, HbA1c, high-sensitivity CRP (hs-CRP) determined by cervical artery echography, and pulse wave velocity (PWV) were measured before/after 12-week drug administra-tion. Significant decreases in HbA1c and HOMAIR were noted in the pioglitazone group, along with significant decreases in TG, AST, ALT, blood pressure, hs-CRP and PWV. Significant decreases in HbAIc, HOMA-IR, BMI and waist circumference were noted in the metformin group. The pioglitazone group significantly improved the values for ALT, systolic blood pressure, hs-CRP and PWV compared to the metformin group. However, the metformin group demonstrated significant improvement in BMI compared with the pioglitazone group. Using a low dose regimen, pioglitazone significantly improved blood pressure and hepatic function and may be more effective than metformin to reduce risk factors in Japanese diabetic patients with metabolic syndrome at preventing atherosclerosis.",
author = "T. Kato and Y. Sawai and H. Kanayama and H. Taguchi and T. Terabavashi and F. Taki and K. Yamada and Y. Yamazaki and N. Hayakawa and Atsushi Suzuki and N. Oda and N. Katada and M. Itoh",
year = "2009",
month = "11",
day = "1",
doi = "10.1055/s-0029-1202792",
language = "English",
volume = "117",
pages = "593--599",
journal = "Experimental and Clinical Endocrinology and Diabetes",
issn = "0947-7349",
publisher = "Thieme",
number = "10",

}

Kato, T, Sawai, Y, Kanayama, H, Taguchi, H, Terabavashi, T, Taki, F, Yamada, K, Yamazaki, Y, Hayakawa, N, Suzuki, A, Oda, N, Katada, N & Itoh, M 2009, 'Comparative Study of Low-dose Pioglitazone or Metformin Treatment in Ia pa nese Diabetic Patients with Metabolic Syndrome', Experimental and Clinical Endocrinology and Diabetes, vol. 117, no. 10, pp. 593-599. https://doi.org/10.1055/s-0029-1202792

Comparative Study of Low-dose Pioglitazone or Metformin Treatment in Ia pa nese Diabetic Patients with Metabolic Syndrome. / Kato, T.; Sawai, Y.; Kanayama, H.; Taguchi, H.; Terabavashi, T.; Taki, F.; Yamada, K.; Yamazaki, Y.; Hayakawa, N.; Suzuki, Atsushi; Oda, N.; Katada, N.; Itoh, M.

In: Experimental and Clinical Endocrinology and Diabetes, Vol. 117, No. 10, 01.11.2009, p. 593-599.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparative Study of Low-dose Pioglitazone or Metformin Treatment in Ia pa nese Diabetic Patients with Metabolic Syndrome

AU - Kato, T.

AU - Sawai, Y.

AU - Kanayama, H.

AU - Taguchi, H.

AU - Terabavashi, T.

AU - Taki, F.

AU - Yamada, K.

AU - Yamazaki, Y.

AU - Hayakawa, N.

AU - Suzuki, Atsushi

AU - Oda, N.

AU - Katada, N.

AU - Itoh, M.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - The aim of this study was to determine whether a relatively low dose of pioglitazone or metformin was effective in diabetic patients with metabolic syndrome. Fifty diabetic patients with metabolic syndrome were randomly assigned to a low-dose pioglitazone (15mg/day) treatment group or a low-dose metformin (500mg/day) treatment group. Drugs were administered for 12 weeks. Systolic and diastolic blood pressure, heart rate, body mass index, triglyceride (TC), HDL and LDLcholesterol, fasting plasma glucose (FPG), fasting plasma insulin (IRI), postprandial glucose, and HOMA-IR in the 75gOGTT, HbA1c, high-sensitivity CRP (hs-CRP) determined by cervical artery echography, and pulse wave velocity (PWV) were measured before/after 12-week drug administra-tion. Significant decreases in HbA1c and HOMAIR were noted in the pioglitazone group, along with significant decreases in TG, AST, ALT, blood pressure, hs-CRP and PWV. Significant decreases in HbAIc, HOMA-IR, BMI and waist circumference were noted in the metformin group. The pioglitazone group significantly improved the values for ALT, systolic blood pressure, hs-CRP and PWV compared to the metformin group. However, the metformin group demonstrated significant improvement in BMI compared with the pioglitazone group. Using a low dose regimen, pioglitazone significantly improved blood pressure and hepatic function and may be more effective than metformin to reduce risk factors in Japanese diabetic patients with metabolic syndrome at preventing atherosclerosis.

AB - The aim of this study was to determine whether a relatively low dose of pioglitazone or metformin was effective in diabetic patients with metabolic syndrome. Fifty diabetic patients with metabolic syndrome were randomly assigned to a low-dose pioglitazone (15mg/day) treatment group or a low-dose metformin (500mg/day) treatment group. Drugs were administered for 12 weeks. Systolic and diastolic blood pressure, heart rate, body mass index, triglyceride (TC), HDL and LDLcholesterol, fasting plasma glucose (FPG), fasting plasma insulin (IRI), postprandial glucose, and HOMA-IR in the 75gOGTT, HbA1c, high-sensitivity CRP (hs-CRP) determined by cervical artery echography, and pulse wave velocity (PWV) were measured before/after 12-week drug administra-tion. Significant decreases in HbA1c and HOMAIR were noted in the pioglitazone group, along with significant decreases in TG, AST, ALT, blood pressure, hs-CRP and PWV. Significant decreases in HbAIc, HOMA-IR, BMI and waist circumference were noted in the metformin group. The pioglitazone group significantly improved the values for ALT, systolic blood pressure, hs-CRP and PWV compared to the metformin group. However, the metformin group demonstrated significant improvement in BMI compared with the pioglitazone group. Using a low dose regimen, pioglitazone significantly improved blood pressure and hepatic function and may be more effective than metformin to reduce risk factors in Japanese diabetic patients with metabolic syndrome at preventing atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=70450265353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450265353&partnerID=8YFLogxK

U2 - 10.1055/s-0029-1202792

DO - 10.1055/s-0029-1202792

M3 - Article

C2 - 19924605

AN - SCOPUS:70450265353

VL - 117

SP - 593

EP - 599

JO - Experimental and Clinical Endocrinology and Diabetes

JF - Experimental and Clinical Endocrinology and Diabetes

SN - 0947-7349

IS - 10

ER -